|76.27||+0.1300||+0.17%||Vol 13.91M||1Y Perf -1.38%|
|Jun 11th, 2021 16:02 DELAYED|
|- -||0.14 0.18%|
|Target Price||93.40||Analyst Rating||Strong Buy 1.50|
|Potential %||22.46||Finscreener Ranking||★★★ 49.65|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 53.53|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 56.35|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★+ 43.52|
|Market Cap||193.12B||Earnings Rating||Buy|
|Price Range Ratio 52W %||28.34||Earnings Date||30th Jul 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||30th Jul 2021|
|Estimated EPS Next Report||1.58|
|EPS Growth Next 5 Years %||6.10|
|Avg. Weekly Volume||13.70M|
|Avg. Monthly Volume||11.93M|
|Avg. Quarterly Volume||12.40M|
Merck & Company Inc. (new) (NYSE: MRK) stock closed at 76.27 per share at the end of the most recent trading day (a 0.17% change compared to the prior day closing price) with a volume of 13.93M shares and market capitalization of 193.12B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 74000 people. Merck & Company Inc. (new) CEO is Kenneth C. Frazier.
The one-year performance of Merck & Company Inc. (new) stock is -1.38%, while year-to-date (YTD) performance is -6.76%. MRK stock has a five-year performance of 36.34%. Its 52-week range is between 71.71 and 87.8, which gives MRK stock a 52-week price range ratio of 28.34%
Merck & Company Inc. (new) currently has a PE ratio of 26.90, a price-to-book (PB) ratio of 6.96, a price-to-sale (PS) ratio of 3.84, a price to cashflow ratio of 16.60, a PEG ratio of 2.32, a ROA of 7.76%, a ROC of 13.66% and a ROE of 25.64%. The company’s profit margin is 14.81%, its EBITDA margin is 27.00%, and its revenue ttm is $48.02 Billion , which makes it $18.96 revenue per share.
Of the last four earnings reports from Merck & Company Inc. (new), there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.58 for the next earnings report. Merck & Company Inc. (new)’s next earnings report date is 30th Jul 2021.
The consensus rating of Wall Street analysts for Merck & Company Inc. (new) is Strong Buy (1.5), with a target price of $93.4, which is +22.46% compared to the current price. The earnings rating for Merck & Company Inc. (new) stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Merck & Company Inc. (new) has a dividend yield of 3.57% with a dividend per share of $2.60 and a payout ratio of 89.00%.
Merck & Company Inc. (new) has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.39, ATR14 : 5.72, CCI20 : -424.75, Chaikin Money Flow : -0.13, MACD : -0.74, Money Flow Index : 28.49, ROC : -1.59, RSI : 50.41, STOCH (14,3) : 94.75, STOCH RSI : 1.00, UO : 88.39, Williams %R : -5.25), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Merck & Company Inc. (new) in the last 12-months were: Caroline Litchfield (Option Excercise at a value of $197 398), David Michael Williams (Option Excercise at a value of $104 098), Dean Y. Li (Option Excercise at a value of $185 340), Frank Clyburn (Option Excercise at a value of $636 757), Frank Clyburn (Sold 57 076 shares of value $4 591 986 ), Jennifer Zachary (Option Excercise at a value of $438 557), Julie L. Gerberding (Option Excercise at a value of $0), Julie L. Gerberding (Sold 36 285 shares of value $2 902 976 ), Kenneth C. Frazier (Sold 560 000 shares of value $45 594 022 ), Lisa LeCointe-Cephas (Option Excercise at a value of $131 626), Michael J. Mcnally (Option Excercise at a value of $173 560), Rita A. Karachun (Option Excercise at a value of $224 400), Robert M. Davis (Option Excercise at a value of $0), Robert M. Davis (Sold 502 546 shares of value $40 720 648 ), Sanat Chattopadhyay (Sold 10 380 shares of value $861 676 ), Steven C. Mizell (Option Excercise at a value of $347 121)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.